ANI Pharmaceuticals, Inc. ANIP
Regular-session close
After hours · Nov 19, 4:28 PM ET
- YTD
- -12.43%
- 1 year
- -13.94%
5D -1.14 (-1.60%)
- Market cap
- 1.57B
- Revenue (ttm)
- 1.04B
- Profit margin
- 11.22%
- EPS (ttm)
- 4.93
- Shares out
- 22.72M
- P/E ratio
- 14.02
- Forward P/E
- 6.78
- YTD return
- -12.43%
- 1-year return
- -13.94%
- 50-day average
- 72.32
- Volume
- 264.29K
- Avg volume
- 423.52K
- Open
- 70.78
- Previous close
- 71.47
- Day's range
- 68.91 – 71.10
- 52-week range
- 67.14 – 87.76
- Beta
- 0.47
- Analysts
- Buy
- Price target
- 103.38 (+49.5%)
- Earnings date
- Feb 26, 2027
Key statistics
- 200-day average
- 76.86
- Enterprise value
- 1.69B
- PEG ratio
- 1.76
- Price / sales
- 1.51
- Price / book
- 2.32
- Revenue growth
- 27.60%
- Free cash flow
- 184.05M
- Total cash
- 436.97M
- Total debt
- 617.36M
- Return on equity
- 20.45%
- Short % of float
- 19.25%
Fundamental scorecard
18 of 25 checks passed on ANIP’s reported financials
18of 25 checks passed
- Value 4 of 5
- Growth 5 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 85.00
- Target (mean)
- 103.38
- Target (high)
- 121.00
- Strong buy3
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 26, 2027
Expected Feb 26, 2027. Consensus EPS estimate 2.56.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 26, 2027 | Dec 30, 2026 | 2.58 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 2.18 | 2.70 | +0.52 | +23.85% |
| Aug 7, 2026 | Jun 30, 2026 | 2.04 | 2.21 | +0.17 | +8.33% |
| May 8, 2026 | Mar 31, 2026 | 1.28 | 2.05 | +0.77 | +60.16% |
| Feb 27, 2026 | Dec 31, 2025 | 1.99 | 2.33 | +0.34 | +17.09% |
| Nov 7, 2025 | Sep 30, 2025 | 1.74 | 2.04 | +0.30 | +17.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Sep 23, 2026 | Oppenheimer | init | — | Perform |
| Aug 10, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Hold | Hold |
| Jul 17, 2026 | Canaccord Genuity | init | — | Hold |
| Jul 10, 2026 | Guggenheim | reit | Buy | Buy |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- anipharmaceuticals.com
News
ANI Pharmaceuticals to Present at Upcoming December Investor Conference
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock
ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Aberdeen Group plc Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121
ANI Pharmaceuticals Q3 2026 Earnings Call Transcript ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M Estimate
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est
ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease Business
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta
Your note
Sign in to keep a note on ANIP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAREY STEPHEN P. | Chief Financial Officer | Sale | Sep 28, 2026 | 168,993 |
| COOK MEREDITH | General Counsel | Sale | Oct 12, 2026 | 73,424 |
| DAVIS KRISTA | Officer | Sale | Mar 8, 2026 | 51,946 |
| GASSERT CHAD | Officer | Stock Award(Grant) | Feb 25, 2026 | 233,406 |
| GUTWERG ORI | Officer | Sale | Aug 9, 2026 | 75,534 |
| HAUGHEY THOMAS J | Director | Sale | Jun 7, 2026 | 38,878 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.89% | 3,155,865 | 218.16M | Sep 29, 2026 |
| Soleus Capital Management, L.P. | 4.29% | 975,500 | 67.44M | Sep 29, 2026 |
| State Street Corporation | 4.19% | 950,970 | 65.74M | Sep 29, 2026 |
| American Century Companies Inc | 4.02% | 912,647 | 63.09M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.98% | 904,707 | 62.54M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 3.21% | 728,748 | 50.38M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.28% | 1,198,642 | 82.86M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.28% | 745,302 | 51.52M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 609,433 | 42.13M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.33% | 529,877 | 36.63M | Sep 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.13% | 256,300 | 17.72M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.99% | 224,536 | 15.52M | Aug 30, 2026 |
